Clinical Trial

Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this study is to evaluate the overall safety and efficacy of LX102 gene therapy for nAMD.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-12-25; most recent amendment 2026-03-04.
Status change: Recruiting → Active, Not Recruiting 2025-06-26
Trial Details
NCT Number NCT06196840
Lead Sponsor Innostellar Biotherapeutics Co.,Ltd
Conditions Neovascular Age-Related Macular Degeneration
Enrollment 50 participants
Start Date 2024-01-24
Primary Completion 2025-06-24 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2026-03-06